BridgeBio Oncology Therapeutics, Inc.
BBOT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001869105
In the last 90 days, BridgeBio Oncology Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 88 institutions reported holding it in 13F filings for Q3 2026, worth $246.7M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by BridgeBio Oncology Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $184.86 in total
- Insiders trading
- 1
- Net value
- −$184.86
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for BridgeBio Oncology Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Cobo Marc | Principal Accounting Officer | 13,734 | Nov 17, 2026 | 5 |
| Elmelech Idan | COO & Principal Financial Ofcr | 14,152 | Oct 5, 2026 | 3 |
| Beltran Pedro | President and CEO | 43,529 | Oct 5, 2026 | 5 |
| Ben Yong | Chief Med & Dev Officer | 43,529 | Oct 5, 2026 | 4 |
| Chen Bihua | Director, 10% Owner | 6,083,221Indirect | Jul 6, 2026 | 2 |
| McCormick Frank | Director | – | Jun 18, 2026 | 1 |
| Bauer Jake | Director | – | Jun 18, 2026 | 1 |
| Kumar Neil | Director | – | Jun 18, 2026 | 1 |
| Tipirneni Praveen P. | Director | – | Jun 18, 2026 | 1 |
| Kelleher Raymond J. | Director | – | Jun 18, 2026 | 1 |
| Lebowitz Peter F | Director | – | Jun 18, 2026 | 2 |
| Mehra Uneek | Other: Former Officer | 22,806 | May 5, 2026 | 2 |
| Wallace Eli M. | Chief Executive Officer | – | Jan 5, 2026 | 2 |
| BridgeBio Pharma, Inc. | 10% Owner | 14,589,846 | Oct 16, 2025 | 0 |
| BridgeBio Pharma LLC | 10% Owner | 14,589,846 | Oct 16, 2025 | 0 |
| Schmid John P. | Other: Former Director | 30,000 | Aug 11, 2025 | 0 |
| McKenna Mark C. | Other: Former Director | 30,000 | Aug 11, 2025 | 0 |
| Tripp Caleb | Chief Financial Officer | – | Aug 11, 2025 | 0 |
| Obradovic Nebojsa | Chief Legal Officer | – | Aug 11, 2025 | 0 |
| Holman Albert A III | Other: Former Director | 30,000 | Aug 11, 2025 | 0 |
| Helix Holdings II LLC | Director, 10% Owner | 509,000Indirect | Feb 10, 2025 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 17, 2026 (view filing)4:35 PM ET | Nov 13 | 4 days | Cobo MarcPrincipal Accounting Officer | SSale | −78 | $2.37 | −$184.86 | −0.6%13.7K after | 10b5-1 |
| Feb 13, 2024 (view filing) | Feb 13 | Same day | Chen BihuaCEO and Chairperson | PPurchaseClass A Ordinary Shares | +2.40M | $10.00 | +$24.0M | New position903.6K after | 3 lots |